CA3079742A1 - Topical formulations containing vitamin a and uses thereof - Google Patents
Topical formulations containing vitamin a and uses thereof Download PDFInfo
- Publication number
- CA3079742A1 CA3079742A1 CA3079742A CA3079742A CA3079742A1 CA 3079742 A1 CA3079742 A1 CA 3079742A1 CA 3079742 A CA3079742 A CA 3079742A CA 3079742 A CA3079742 A CA 3079742A CA 3079742 A1 CA3079742 A1 CA 3079742A1
- Authority
- CA
- Canada
- Prior art keywords
- oil
- vitamin
- analogs
- derivatives
- retinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 title claims abstract description 26
- 229940045997 vitamin a Drugs 0.000 title claims abstract description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 239000003921 oil Substances 0.000 claims abstract description 24
- 235000019198 oils Nutrition 0.000 claims abstract description 24
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 23
- 238000009472 formulation Methods 0.000 claims abstract description 23
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940046009 vitamin E Drugs 0.000 claims abstract description 23
- 239000011709 vitamin E Substances 0.000 claims abstract description 23
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 23
- 239000003205 fragrance Substances 0.000 claims abstract description 17
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 16
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 15
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 15
- 239000011719 vitamin A Substances 0.000 claims abstract description 15
- 235000019489 Almond oil Nutrition 0.000 claims abstract description 13
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 13
- 239000004098 Tetracycline Substances 0.000 claims abstract description 13
- 239000008168 almond oil Substances 0.000 claims abstract description 13
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 13
- 239000003240 coconut oil Substances 0.000 claims abstract description 13
- 235000008524 evening primrose extract Nutrition 0.000 claims abstract description 13
- 239000010475 evening primrose oil Substances 0.000 claims abstract description 13
- 229940089020 evening primrose oil Drugs 0.000 claims abstract description 13
- 229940119170 jojoba wax Drugs 0.000 claims abstract description 13
- 239000003120 macrolide antibiotic agent Substances 0.000 claims abstract description 13
- 229940041033 macrolides Drugs 0.000 claims abstract description 13
- 239000010667 rosehip oil Substances 0.000 claims abstract description 13
- 235000019364 tetracycline Nutrition 0.000 claims abstract description 13
- 150000003522 tetracyclines Chemical class 0.000 claims abstract description 13
- 229940040944 tetracyclines Drugs 0.000 claims abstract description 13
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 10
- 206010000496 acne Diseases 0.000 claims abstract description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 7
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 7
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 7
- 208000002177 Cataract Diseases 0.000 claims abstract description 6
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 6
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 5
- 241001303601 Rosacea Species 0.000 claims abstract description 5
- 230000032683 aging Effects 0.000 claims abstract description 5
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 5
- 201000004700 rosacea Diseases 0.000 claims abstract description 5
- 230000004064 dysfunction Effects 0.000 claims abstract description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 33
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 30
- 229960000342 retinol acetate Drugs 0.000 claims description 18
- 235000019173 retinyl acetate Nutrition 0.000 claims description 18
- 239000011770 retinyl acetate Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 229940108325 retinyl palmitate Drugs 0.000 claims description 15
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 15
- 239000011769 retinyl palmitate Substances 0.000 claims description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 14
- 241000157835 Gardenia Species 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- 229940067606 lecithin Drugs 0.000 claims description 8
- 235000010445 lecithin Nutrition 0.000 claims description 8
- 239000000787 lecithin Substances 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000001126 Keratosis Diseases 0.000 claims description 4
- 230000002500 effect on skin Effects 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 206010000503 Acne cystic Diseases 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 206010021197 Ichthyoses Diseases 0.000 claims description 2
- 208000012999 benign epithelial neoplasm Diseases 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 208000000069 hyperpigmentation Diseases 0.000 claims description 2
- 230000003810 hyperpigmentation Effects 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 230000003780 keratinization Effects 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 230000003746 surface roughness Effects 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 32
- 230000000699 topical effect Effects 0.000 abstract description 7
- 239000000499 gel Substances 0.000 abstract description 4
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 230000000676 anti-immunogenic effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 230000000711 cancerogenic effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 30
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 206010057430 Retinal injury Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000004304 visual acuity Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000271274 Cleopatra Species 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to topical skin care formulations comprising vitamin A, typically as acetate of palmitate, vitamin E, almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, PLO gel, and tetracyclines or macrolides. The medicinal uses may also include, but are not limited to eczema, acne, psoriasis, atopic dermatitis, rosacea, and dermatitis, but may include the topical treatment of retinal disorders consisting of: glaucoma, corneal dysfunction, adult macular degeneration, cataracts, and diabetic retinopathy. The topical formulations may also be used to treat carcinogenic effects via anti-inflammatory and immunogenic properties. The cosmetic uses may include, but are not limited to, anti-wrinkle effects as an incident of aging.
Description
Docket No.: 0 184-5 3 CAPT2 Patent TOPICAL FORMULATIONS CONTAINING VITAMIN A AND USES THEREOF
FIELD OF THE INVENTION
The present disclosure relates to topical formulations, particularly to formulations used in the field of skin care and more particularly to therapeutic uses of formulations comprising vitamin A, vitamin E, and various essential oils and mild fragrances and combinations thereof.
BACKGROUND
Skin care has been practiced for thousands of years, dating back to the Ancient Egyptians. Cleopatra was known for her skin care regimen and is said to have discovered .. some of the first anti-aging methods. Skin care has evolved through the years with every generation being eager to slow, prevent or reverse the aging process, prevent acne, and heal skin. Countless skin care products are commercially available for beautification of the skin and to fight wrinkle formation.
The effectiveness of all skin care products is normally contingent upon delivery of the active ingredients therein through the stratum corneum and viable epidermis into the dermis layer of the skin structure. This is because the active ingredients in the skin care product cannot be effective unless they penetrate through the dead layers of skin tissue and into the dermis layer of living skin cells. This is normally a difficult proposition for water soluble active ingredients, such as ascorbic acid, because the stratum corneum is a good .. water barrier. The stratum corneum and viable epidermis act to protect the body by holding water therein to prevent dehydration and by keeping external water which is frequently contaminated out of the body.
Retinoids are a group of compounds that include retinol (Vitamin A), retinal, numerous retinoic acids, esters and similar derivatives. Many retinoids have useful skin-treatment properties and have been used extensively to treat acne vulgaris.
However the use several compounds have been limited because of their irritancy or toxicity when administered in excess. Other compounds are unstable under exposure to heat, oxygen, and ultraviolet light of have highly teratogenic and mutagenic effects.
Treatment of acne and other skin conditions can be difficult. A suitable solution is desired. Various attempts have been made to solve problems found in topical formulations Date Recue/Date Received 2020-04-28 Docket No.: 0 184-5 3 CAPT2 Patent for skin care art. Among these are found in: U.S. Patent and Publication Nos.
8,912,175;
4,885,311; and 2002/0155180. This prior art is representative of topical formulations for skin care.
None of the above cited documents, taken either singly or in combination, is seen to describe embodiments of the invention as claimed. Thus, a need exists for a reliable topical formulation for skin care, and to avoid the above-mentioned problems.
BRIEF SUMMARY
It is an object of the invention to provide topical formulations containing vitamin A
and uses thereof.
In accordance with an aspect of the invention there is provided a topical formulation comprising: one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof; one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and Pluronic Lecithin Organogel.
In accordance with another aspect of the invention there is provided a method for treating a skin condition selected from the group consisting of acne vulgaris, cystic acne, eczema, psoriasis, atopic dermatitis, rosacea, dermatitis, hyper-pigmentation, dermal hypoplasia, epidermal hypoplasia, dermal keratosis, epidermal keratoses, wrinkles of the skin as an incident of aging, enlarged pores, surface roughness, ichthyoses, follicular disorders, benign epithelial tumors, perforated dermatoses, disorders of keratinization, and combinations thereof, comprising topically applying to skin affected by the skin condition, a composition comprising: one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof; one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and Pluronic Lecithin Organogel.
In accordance with an additional aspect of the invention there is provided a method for treating retinal disorders selected from the group consisting of, glaucoma, corneal dysfunction, adult macular degeneration, cataracts, diabetic retinopathy and combinations thereof, comprising topically applying to skin surrounding an ocular region, a composition comprising: one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives
FIELD OF THE INVENTION
The present disclosure relates to topical formulations, particularly to formulations used in the field of skin care and more particularly to therapeutic uses of formulations comprising vitamin A, vitamin E, and various essential oils and mild fragrances and combinations thereof.
BACKGROUND
Skin care has been practiced for thousands of years, dating back to the Ancient Egyptians. Cleopatra was known for her skin care regimen and is said to have discovered .. some of the first anti-aging methods. Skin care has evolved through the years with every generation being eager to slow, prevent or reverse the aging process, prevent acne, and heal skin. Countless skin care products are commercially available for beautification of the skin and to fight wrinkle formation.
The effectiveness of all skin care products is normally contingent upon delivery of the active ingredients therein through the stratum corneum and viable epidermis into the dermis layer of the skin structure. This is because the active ingredients in the skin care product cannot be effective unless they penetrate through the dead layers of skin tissue and into the dermis layer of living skin cells. This is normally a difficult proposition for water soluble active ingredients, such as ascorbic acid, because the stratum corneum is a good .. water barrier. The stratum corneum and viable epidermis act to protect the body by holding water therein to prevent dehydration and by keeping external water which is frequently contaminated out of the body.
Retinoids are a group of compounds that include retinol (Vitamin A), retinal, numerous retinoic acids, esters and similar derivatives. Many retinoids have useful skin-treatment properties and have been used extensively to treat acne vulgaris.
However the use several compounds have been limited because of their irritancy or toxicity when administered in excess. Other compounds are unstable under exposure to heat, oxygen, and ultraviolet light of have highly teratogenic and mutagenic effects.
Treatment of acne and other skin conditions can be difficult. A suitable solution is desired. Various attempts have been made to solve problems found in topical formulations Date Recue/Date Received 2020-04-28 Docket No.: 0 184-5 3 CAPT2 Patent for skin care art. Among these are found in: U.S. Patent and Publication Nos.
8,912,175;
4,885,311; and 2002/0155180. This prior art is representative of topical formulations for skin care.
None of the above cited documents, taken either singly or in combination, is seen to describe embodiments of the invention as claimed. Thus, a need exists for a reliable topical formulation for skin care, and to avoid the above-mentioned problems.
BRIEF SUMMARY
It is an object of the invention to provide topical formulations containing vitamin A
and uses thereof.
In accordance with an aspect of the invention there is provided a topical formulation comprising: one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof; one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and Pluronic Lecithin Organogel.
In accordance with another aspect of the invention there is provided a method for treating a skin condition selected from the group consisting of acne vulgaris, cystic acne, eczema, psoriasis, atopic dermatitis, rosacea, dermatitis, hyper-pigmentation, dermal hypoplasia, epidermal hypoplasia, dermal keratosis, epidermal keratoses, wrinkles of the skin as an incident of aging, enlarged pores, surface roughness, ichthyoses, follicular disorders, benign epithelial tumors, perforated dermatoses, disorders of keratinization, and combinations thereof, comprising topically applying to skin affected by the skin condition, a composition comprising: one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof; one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and Pluronic Lecithin Organogel.
In accordance with an additional aspect of the invention there is provided a method for treating retinal disorders selected from the group consisting of, glaucoma, corneal dysfunction, adult macular degeneration, cataracts, diabetic retinopathy and combinations thereof, comprising topically applying to skin surrounding an ocular region, a composition comprising: one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives
2 Date Recue/Date Received 2020-04-28 Docket No.: 0 184-5 3 CAPT2 Patent or analogs thereof; one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and Pluronic Lecithin Organogel.
The advantages and features of the present invention will become better understood with reference to the following more detailed description and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
The figure which accompanies the written portion of this specification illustrate embodiments and method(s) of use for the present invention, skin treatment topical formulation, constructed and operative according to the teachings of the present invention.
Table 1 is a summary of the patient demographics relating to a clinical trial using a composition of a skin treatment topical formulation according to an embodiment of the present invention.
DETAILED DESCRIPTION
Formulations and methods for carrying out the invention are presented in terms of embodiments described herein. However, the invention is not limited to the described embodiments, and a person skilled in the art will appreciate that many other embodiments of the invention are possible without deviating from the basic concept of the invention, and that any such work around will also fall under scope of this invention. It is envisioned that other styles and configurations of the present invention can be easily incorporated into the teachings of the present invention, and the configurations shall be shown and described for purposes of clarity and disclosure and not by way of limitation of scope.
Embodiments of the present invention provide a safe and effective combination of active agents characterized by synergistic activity, and which is particularly useful in the treatment of skin disorders and the topical treatment of retinal disorders.
The combined active agents include at least one retinoid, particularly selected from a class of retinoids that are non-irritating to skin, and a combination of vitamins and essential oils and mild fragrances. The combination of these active ingredients provides a skin treatment formulation characterized by rapid onset of activity and lack of skin irritation.
The present invention describes topical formulations and their cosmetic and medicinal uses. The formulations consist of various derivatives, analogs and isomers of
The advantages and features of the present invention will become better understood with reference to the following more detailed description and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
The figure which accompanies the written portion of this specification illustrate embodiments and method(s) of use for the present invention, skin treatment topical formulation, constructed and operative according to the teachings of the present invention.
Table 1 is a summary of the patient demographics relating to a clinical trial using a composition of a skin treatment topical formulation according to an embodiment of the present invention.
DETAILED DESCRIPTION
Formulations and methods for carrying out the invention are presented in terms of embodiments described herein. However, the invention is not limited to the described embodiments, and a person skilled in the art will appreciate that many other embodiments of the invention are possible without deviating from the basic concept of the invention, and that any such work around will also fall under scope of this invention. It is envisioned that other styles and configurations of the present invention can be easily incorporated into the teachings of the present invention, and the configurations shall be shown and described for purposes of clarity and disclosure and not by way of limitation of scope.
Embodiments of the present invention provide a safe and effective combination of active agents characterized by synergistic activity, and which is particularly useful in the treatment of skin disorders and the topical treatment of retinal disorders.
The combined active agents include at least one retinoid, particularly selected from a class of retinoids that are non-irritating to skin, and a combination of vitamins and essential oils and mild fragrances. The combination of these active ingredients provides a skin treatment formulation characterized by rapid onset of activity and lack of skin irritation.
The present invention describes topical formulations and their cosmetic and medicinal uses. The formulations consist of various derivatives, analogs and isomers of
3 Date Recue/Date Received 2020-04-28 Docket No.: 0 184-5 3 CAPT2 Patent vitamin A. Specifically retinyl acetate and retinyl palmitate. The formulations may contain various different active and non-active components including derivatives, analogs and isomers of vitamin E and various essential oils and mild fragrances. The non-active base of the formulation may be a cream, foam, gel, lotion or an ointment.
The medicinal uses may include, but are not limited to, the topical treatment of skin disorders consisting of: eczema, acne, psoriasis, atopic dermatitis, rosacea, and dermatitis.
The medicinal uses may also include, but are not limited to, the topical treatment of retinal disorders consisting of: glaucoma, corneal dysfunction, adult macular degeneration, cataracts, and diabetic retinopathy.
The medicinal uses may also include, but are not limited to, anticarcinogenic effects via anti-inflammatory and immunogenic properties.
The cosmetic uses may include, but are not limited to, anti-wrinkle effects as an incident of aging.
Embodiments of the present invention are directed to skin treatment topical formulations for dermatological conditions for external application to the affected areas 1-2x/day. The objective of topical formulations is to overcome systemic adverse effects. The formulations are effective in the treatment of challenging illnesses, requiring additional treatments for adverse effects from oral or injectable forms in addition to the extreme cost.
In one embodiment of the present invention, skin treatment topical formulations may comprise vitamin A acetate U.S.P, vitamin E, almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, PLO gel, and tetracyclines or macrolides 1-1.5% w/w.
In an additional embodiment of the present invention, skin treatment topical formulations may comprise vitamin A palmitate U.S.P, vitamin E, almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, PLO
gel, and tetracyclines or macrolides 1-1.5% w/w.
The topical embodiments of the present invention are typically formulated in PLO
gel also known as Pluronic Lecithin Organogel. PLO gel is a mixture of oil and water that thickens to form a gel comprising lecithin, and isopropyl palmitate.
The medicinal uses may include, but are not limited to, the topical treatment of skin disorders consisting of: eczema, acne, psoriasis, atopic dermatitis, rosacea, and dermatitis.
The medicinal uses may also include, but are not limited to, the topical treatment of retinal disorders consisting of: glaucoma, corneal dysfunction, adult macular degeneration, cataracts, and diabetic retinopathy.
The medicinal uses may also include, but are not limited to, anticarcinogenic effects via anti-inflammatory and immunogenic properties.
The cosmetic uses may include, but are not limited to, anti-wrinkle effects as an incident of aging.
Embodiments of the present invention are directed to skin treatment topical formulations for dermatological conditions for external application to the affected areas 1-2x/day. The objective of topical formulations is to overcome systemic adverse effects. The formulations are effective in the treatment of challenging illnesses, requiring additional treatments for adverse effects from oral or injectable forms in addition to the extreme cost.
In one embodiment of the present invention, skin treatment topical formulations may comprise vitamin A acetate U.S.P, vitamin E, almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, PLO gel, and tetracyclines or macrolides 1-1.5% w/w.
In an additional embodiment of the present invention, skin treatment topical formulations may comprise vitamin A palmitate U.S.P, vitamin E, almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, PLO
gel, and tetracyclines or macrolides 1-1.5% w/w.
The topical embodiments of the present invention are typically formulated in PLO
gel also known as Pluronic Lecithin Organogel. PLO gel is a mixture of oil and water that thickens to form a gel comprising lecithin, and isopropyl palmitate.
4 Date Recue/Date Received 2020-04-28 Docket No.: 0 184-5 3 CAPT2 Patent Skin treatment topical formulation may be used for treatment of acne, eczema, psoriasis atopic dermatitis and other illnesses via topical formulations consisting of retinyl acetate with or without antibiotics. Retinyl acetate U.S.P. or retinal palmitate in adequate concentration as permitted (0.1% to 1.85% w/w) is mixed with vitamin E and various essential oils, mild fragrance supplemented with a base consisting of lipophilic/lipophobic products available from compounding suppliers. The application of antibiotics incorporation depends on results observed. In treatment resistant cases, antibiotics may be added. A
concentration of antibiotic ranges from 1-4%. The duration of such treatment is limited to 8-12 weeks to avoid incidences of microbial resistance.
An alternative embodiment of the composition may include retinyl acetate or retinyl palmitate 0.3-1.85% w/w, and optionally an antibiotic 1-4% (tetracyclines or macrolides).
An alternative embodiment of the composition may include retinyl acetate or retinyl palmitate 1.50-1.85% w/w, and optionally an antibiotic 1-4% (tetracyclines or macrolides).
An alternative embodiment of the composition may include retinyl acetate or retinyl palmitate 1.5 w/w and optionally an antibiotic1-4% (tetracyclines or macrolides).
Formulation 1A:
Retinyl acetate U.S.P (0.1-1.85% w/w), vitamin E (0.1 ¨ 1.85 % w/w), tetracyclines or macrolides (1.0-4.0% w/w), and one or more oils selected from: almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, in a PLO gel.
Formulation 1B:
Retinyl acetate U.S.P (1.5% w/w), vitamin E (1.0 % w/w), and optionally tetracyclines or macrolides (1.0% w/w), and one or more oils selected from:
almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, in a PLO
gel Formulation 2A:
Retinyl palmitate U.S.P (0.1-1.85% w/w) vitamin E (0.1 ¨ 1.85 % w/w), optionally including tetracyclines or macrolides (1.0-4.0% by weight), and one or more oils selected from: almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, in a PLO gel.
concentration of antibiotic ranges from 1-4%. The duration of such treatment is limited to 8-12 weeks to avoid incidences of microbial resistance.
An alternative embodiment of the composition may include retinyl acetate or retinyl palmitate 0.3-1.85% w/w, and optionally an antibiotic 1-4% (tetracyclines or macrolides).
An alternative embodiment of the composition may include retinyl acetate or retinyl palmitate 1.50-1.85% w/w, and optionally an antibiotic 1-4% (tetracyclines or macrolides).
An alternative embodiment of the composition may include retinyl acetate or retinyl palmitate 1.5 w/w and optionally an antibiotic1-4% (tetracyclines or macrolides).
Formulation 1A:
Retinyl acetate U.S.P (0.1-1.85% w/w), vitamin E (0.1 ¨ 1.85 % w/w), tetracyclines or macrolides (1.0-4.0% w/w), and one or more oils selected from: almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, in a PLO gel.
Formulation 1B:
Retinyl acetate U.S.P (1.5% w/w), vitamin E (1.0 % w/w), and optionally tetracyclines or macrolides (1.0% w/w), and one or more oils selected from:
almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, in a PLO
gel Formulation 2A:
Retinyl palmitate U.S.P (0.1-1.85% w/w) vitamin E (0.1 ¨ 1.85 % w/w), optionally including tetracyclines or macrolides (1.0-4.0% by weight), and one or more oils selected from: almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, in a PLO gel.
5 Date Recue/Date Received 2020-04-28 Docket No.: 0 184-5 3 CAPT2 Patent Formulation 2B:
Retinyl palmitate U.S.P (1.5% w/w), vitamin E (1.0 % w/w), optionally including tetracyclines or macrolides (1.0% w/w), and one or more oils selected from:
almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, in a PLO
gel.
Treatment of Diabetic Retinopathy and Other Retinal Disorders.
Disorders associated with diabetes commonly include a decreased vision to blindness and cataract formation. A focus of this study was to determine a beneficial role of vitamin A
applied through the principle of transdermal absorption. The cream based topical .. Formulation 2B was used in this study.
The objective was to avoid having systemic adverse effects. The duration of treatments was found to be optimal for 12-16 weeks. Twenty seven subjects, or both genders, were studied for a duration of 12-16 weeks and periodically visual acuity was assessed by using Snellen charts in the office or symptoms evaluations, in cases of patients with retinal injuries. The results obtained was patients showing increased visual acuity mainly in daytime vision (cone regeneration).
Preparation of Formulation 2B - Vitamin A in the form of retinyl palmitate was weighed to render a concentration as permitted by Health Canada. In addition, various essential oils were added and incorporated into a lip balm base at a warmer temperature to provide a homogeneous mixture. Samples weighing 12 grams. Each were given to patients on trial and they were seen in a follow-up every 4 weeks.
The mode of administration was applying Formulation 2B twice a day externally on upper and lower eye lids. Assessments of visual acuity changes were determined by Snellen chart, and in cases of retinal injuries ophthalmological consultation was done.
The parameters of study considered are age of the patient, duration of diabetes the patient has endured and resolution of symptoms (time required of treatment to see improvements in visual acuity to a near normal level). A duration of treatment needed for a satisfactory improvement may have been dependent on the level of glycemic control i.e.
Sub-optimal control would reflect a longer need of treatment. In addition, rg represents
Retinyl palmitate U.S.P (1.5% w/w), vitamin E (1.0 % w/w), optionally including tetracyclines or macrolides (1.0% w/w), and one or more oils selected from:
almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil, gardenia fragrance oil, in a PLO
gel.
Treatment of Diabetic Retinopathy and Other Retinal Disorders.
Disorders associated with diabetes commonly include a decreased vision to blindness and cataract formation. A focus of this study was to determine a beneficial role of vitamin A
applied through the principle of transdermal absorption. The cream based topical .. Formulation 2B was used in this study.
The objective was to avoid having systemic adverse effects. The duration of treatments was found to be optimal for 12-16 weeks. Twenty seven subjects, or both genders, were studied for a duration of 12-16 weeks and periodically visual acuity was assessed by using Snellen charts in the office or symptoms evaluations, in cases of patients with retinal injuries. The results obtained was patients showing increased visual acuity mainly in daytime vision (cone regeneration).
Preparation of Formulation 2B - Vitamin A in the form of retinyl palmitate was weighed to render a concentration as permitted by Health Canada. In addition, various essential oils were added and incorporated into a lip balm base at a warmer temperature to provide a homogeneous mixture. Samples weighing 12 grams. Each were given to patients on trial and they were seen in a follow-up every 4 weeks.
The mode of administration was applying Formulation 2B twice a day externally on upper and lower eye lids. Assessments of visual acuity changes were determined by Snellen chart, and in cases of retinal injuries ophthalmological consultation was done.
The parameters of study considered are age of the patient, duration of diabetes the patient has endured and resolution of symptoms (time required of treatment to see improvements in visual acuity to a near normal level). A duration of treatment needed for a satisfactory improvement may have been dependent on the level of glycemic control i.e.
Sub-optimal control would reflect a longer need of treatment. In addition, rg represents
6 Date Recue/Date Received 2020-04-28 Docket No.: 0 184-5 3 CAPT2 Patent patients with retinal injuries or glaucoma and rc includes a patient with retinitis and corneal injuries.
Formulation 2B application was found to be free of any side effects. In rare cases one may exhibit hypersensitivity by having erythema in pen-orbital region and or burning sensation. Patients were advised to discontinue using the product in those cases. However, hypersensitivity was of a rare occurrence. As described earlier the extent of treatment needed were variable. Most of the study participants demonstrated visual improvement to a near normal level in 3 to 4 months.
Significant indication of improvement in visual activity mainly daytime cone regeneration based on 4 months observations.
Table 1 indicates the demographics of the patients enrolled in the clinical study.
Cases with most remarkable improvement:
A 75 yrs. Old male with a history of retinal detachment 7 years earlier and resulting blindness, in spite of 4 surgeries, had seen a normal day time vision after a 4 month application of Formulation 2B.
A 57 years old female was diagnosed with retinal injury causing diminished vision and was scheduled for a surgery. She had a full recovery after 12 weeks of using the cream and was informed of not requiring the surgery at the end since the injury had healed.
A 70 years old male had a one-week history of diminishing vision from an acute .. retinal injury in one of his eyes and had experienced full relief of symptoms after using the cream for next 2 weeks.
Formulation 1A and Formulation 2A were initially formulated for the treatment of various forms of dermatitis (resistant to oral treatments), glaucoma, adult macular degeneration and cataracts prevention. The Formulations have also been the subject of clinical observations have shown beneficial role in eczema, acne, psoriasis, atopic dermatitis, rosacea, and dermatitis.
The skin treatment topical formulation includes a composition used for treatment of acne, eczema, psoriasis atopic dermatitis and other illnesses. The composition may be created using vitamin A acetate 1-1.5% (0.5 ml each), and vitamin E in equal proportion to vitamin A acetate. Antibiotics may be included in the composition for effective treatment.
Formulation 2B application was found to be free of any side effects. In rare cases one may exhibit hypersensitivity by having erythema in pen-orbital region and or burning sensation. Patients were advised to discontinue using the product in those cases. However, hypersensitivity was of a rare occurrence. As described earlier the extent of treatment needed were variable. Most of the study participants demonstrated visual improvement to a near normal level in 3 to 4 months.
Significant indication of improvement in visual activity mainly daytime cone regeneration based on 4 months observations.
Table 1 indicates the demographics of the patients enrolled in the clinical study.
Cases with most remarkable improvement:
A 75 yrs. Old male with a history of retinal detachment 7 years earlier and resulting blindness, in spite of 4 surgeries, had seen a normal day time vision after a 4 month application of Formulation 2B.
A 57 years old female was diagnosed with retinal injury causing diminished vision and was scheduled for a surgery. She had a full recovery after 12 weeks of using the cream and was informed of not requiring the surgery at the end since the injury had healed.
A 70 years old male had a one-week history of diminishing vision from an acute .. retinal injury in one of his eyes and had experienced full relief of symptoms after using the cream for next 2 weeks.
Formulation 1A and Formulation 2A were initially formulated for the treatment of various forms of dermatitis (resistant to oral treatments), glaucoma, adult macular degeneration and cataracts prevention. The Formulations have also been the subject of clinical observations have shown beneficial role in eczema, acne, psoriasis, atopic dermatitis, rosacea, and dermatitis.
The skin treatment topical formulation includes a composition used for treatment of acne, eczema, psoriasis atopic dermatitis and other illnesses. The composition may be created using vitamin A acetate 1-1.5% (0.5 ml each), and vitamin E in equal proportion to vitamin A acetate. Antibiotics may be included in the composition for effective treatment.
7 Date Recue/Date Received 2020-04-28 Docket No.: 0 184-5 3 CAPT2 Patent The application of antibiotics depends on case results observed. In treatment resistant cases, antibiotics may be added. A concentration of antibiotic may range from 1-4%.
The duration of such treatment is limited to 8-12 weeks to avoid incidences of microbial resistance.
The foregoing descriptions of specific embodiments of the present invention have .. been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention and method of use to the precise forms disclosed. Many modifications and variations are possible in light of the above teaching. The embodiments described were chosen and described in order to best explain the principles of the invention and its practical application, and to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. It is understood that various omissions or substitutions of equivalents are contemplated as circumstance may suggest or render expedient, but is intended to cover the application or implementation without departing from the spirit or scope of the claims of the present invention.
The duration of such treatment is limited to 8-12 weeks to avoid incidences of microbial resistance.
The foregoing descriptions of specific embodiments of the present invention have .. been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention and method of use to the precise forms disclosed. Many modifications and variations are possible in light of the above teaching. The embodiments described were chosen and described in order to best explain the principles of the invention and its practical application, and to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. It is understood that various omissions or substitutions of equivalents are contemplated as circumstance may suggest or render expedient, but is intended to cover the application or implementation without departing from the spirit or scope of the claims of the present invention.
8 Date Recue/Date Received 2020-04-28
Claims (17)
1. A topical formulation comprising:
(i) one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof;
(ii) one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and (iii) Pluronic Lecithin Organogel.
(i) one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof;
(ii) one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and (iii) Pluronic Lecithin Organogel.
2. The topical formulation of claim 1, additionally comprising tetracyclines or macrolides.
3. The topical formulation of claim 1, wherein the vitamin A, derivatives or analogs thereof is retinyl acetate.
4. The topical formulation of claim 1, wherein the vitamin A, derivatives or analogs is retinyl palmitate.
5. The topical formulation of claim 1, comprising retinyl acetate and vitamin E.
6. The topical formulation of claim 1, comprising retinyl palmitate and vitamin E.
7. The topical formulation of claim 1, comprising 1.50 ¨ 1.85% w/w retinyl acetate or 1.50 ¨
1.85% w/w retinyl palmitate.
1.85% w/w retinyl palmitate.
8. A method for treating a skin condition selected from the group consisting of acne vulgaris, cystic acne, eczema, psoriasis, atopic dermatitis, rosacea, dermatitis, hyper-pigmentation, dermal hypoplasia, epidermal hypoplasia, dermal keratosis, epidermal keratoses, wrinkles of the skin as an incident of aging, enlarged pores, surface roughness, ichthyoses, follicular disorders, benign epithelial tumors, perforated dermatoses, disorders of keratinization, and combinations thereof, comprising topically applying to skin affected by the skin condition, a composition comprising:
(i) one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof;
(ii) one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and (iii) Pluronic Lecithin Organogel.
(i) one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof;
(ii) one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and (iii) Pluronic Lecithin Organogel.
9. The method of claim 8, wherein the composition comprises: retinyl acetate and vitamin E.
10. The method of claim 8, wherein the composition comprises: retinyl palmitate and vitamin E.
11. The method of claim 8, wherein the composition additionally comprises tetracyclines or macrolides.
12. The method of claim 8, wherein the composition comprises 1.50 ¨ 1.85% w/w retinyl acetate or 1.50 ¨ 1.85% w/w retinyl palmitate.
13. A method for treating retinal disorders selected from the group consisting of, glaucoma, corneal dysfunction, adult macular degeneration, cataracts, diabetic retinopathy and combinations thereof, comprising topically applying to skin surrounding an ocular region, a composition comprising:
(i) one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof;
(ii) one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and (iii) Pluronic Lecithin Organogel.
(i) one or more of vitamin A, derivatives or analogs thereof, vitamin E, derivatives or analogs thereof;
(ii) one or more oils selected from almond oil, rose hip oil, evening primrose oil, coconut oil, jojoba oil; and gardenia fragrance oil; and (iii) Pluronic Lecithin Organogel.
14. The method of claim 13, wherein the composition comprises: retinyl acetate and vitamin E.
15. The method of claim 13, wherein the formulation comprises: retinyl palmitate and vitamin E.
16. The method of claim 13, wherein the formulation additionally comprises tetracyclines or macrolides.
17. The method of claim 13, wherein the composition comprises 1.50 ¨ 1.85% w/w retinyl acetate or 1.50 ¨ 1.85% w/w retinyl palmitate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962829718P | 2019-04-28 | 2019-04-28 | |
US62/839,718 | 2019-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3079742A1 true CA3079742A1 (en) | 2020-10-28 |
Family
ID=73034357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3079742A Abandoned CA3079742A1 (en) | 2019-04-28 | 2020-04-28 | Topical formulations containing vitamin a and uses thereof |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA3079742A1 (en) |
-
2020
- 2020-04-28 CA CA3079742A patent/CA3079742A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5789399A (en) | Treatment of pruritus with vitamin D and analogs thereof | |
DE19615577A1 (en) | Use of salicin as an anti-irritative agent in cosmetic and topical dermatological preparations | |
EP0687467A2 (en) | Cosmetic and dermatological combinations containing glycerylalkylethers as active ingredients | |
US11090205B2 (en) | Methods and compositions for treatment of skin conditions | |
JP4398641B2 (en) | Hypoallergenic and non-irritating skin care preparations | |
US20080057138A1 (en) | Restorative skin cream | |
Gonçalves et al. | Dermocosmetic care for rosacea | |
EP1762241A1 (en) | Compositions and methods for mitigating skin irritation | |
US7604812B2 (en) | Hypoallergenic and non-irritant skin care formulations | |
AU2002234581A1 (en) | Hypoallergenic and non-irritant skin care formulations | |
DE19615575A1 (en) | Use of glucosides and ferulic acid as an anti-irritative agent in cosmetic and topical dermatological preparations | |
US20200338019A1 (en) | Topical formulations containing vitamin a and uses thereof | |
CA3079742A1 (en) | Topical formulations containing vitamin a and uses thereof | |
JP2021521153A (en) | Topical preparations containing strontium and methylsulfonylmethane (MSM) and treatment methods | |
WO2023104843A1 (en) | Topical preparation for enhancing skin condition | |
EP1752132A2 (en) | Skin cosmetic compositions | |
WO1997046221A1 (en) | Cosmetic method for treating and preventing the signs of skin ageing | |
CN110420132B (en) | Whitening skin care composition and preparation method thereof | |
EP1594456B1 (en) | Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions | |
JP2007016025A (en) | Topical composition for skin and method | |
DE202006019185U1 (en) | Moisture aqueous sea buckthorn skin care preparation, useful to nourish and clean skin, which is damaged by cancer therapy, comprises waxes and fats, vitamins, plant hydrolates, moisturizing substances, material mixtures, and pH-regulators | |
DE19615576A1 (en) | New mono: and di:glucoside of glabridin | |
RU2218907C1 (en) | Composition for taking care of facial skin and eyelids | |
US20220133830A1 (en) | Topical composition for control of demodex | |
Draelos | Formulation for special populations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20231030 |